Abstract Breast cancer stem cells (BrCSC) are resistant to common therapeutic modalities including chemotherapy, radiation, and hormonal agents. They are thought to contribute to treatment resistance, relapse, and metastases. This study examines the effect of a monoclonal anti-DR5 antibody (TRA-8) and chemotherapy (adriamycin, taxol) on BrCSC populations from basal-like breast cancer cell lines. Doubly enriched BrCSC (CD44 ? , CD24 -, ALDH ? ) cells were exposed to TRA-8 and control reagents and examined for cytotoxicity, caspase activation, tumorsphere formation and tumorigenicity. Doubly enriched BrCSC populations expressed cell surface DR5 and were sensitive to TRA-8 mediated cytotoxicity with induction of caspase 8 and 3 activation. TRA-8 at sub-nanomolar concentrations inhibited 2LMP and SUM159 BrCSC tumorsphere formation and was more than 50-fold more inhibitory than TRAIL or anti-DR4 at equimolar concentrations. Chemotherapy treatment of 2LMP and SUM159 cell lines resulted in a relative increase of BrCSC, whereas TRA-8 produced a decrease in the percentage of BrCSC. TRA-8 exposure to 2LMP and SUM159 BrCSC preparations produced significant inhibition of tumorigenicity. DR5 maybe a therapeutic target on the surface of basal-like BrCSC which is amenable to agonistic monoclonal anti-DR5 therapy.
Introduction
Basal-like breast cancer accounts for about 15% of all breast cancer [1] . It is characterized by a unique mRNA profile with CK5/6 expression, inactivation of BRCA1 and commonly lacks estrogen receptor, progesterone receptor, and HER-2 amplification [1] [2] [3] . They are further categorized into basal A and basal B subtypes and appear to commonly have substantial numbers of breast cancer stem cells (BrCSC) or tumor initiating cells [4] [5] [6] .
The cancer stem cell hypothesis suggests that tumors, similar to normal tissue, are organized in a cellular hierarchy, with cancer stem cells (CSC) at the top, as the only cells with potentially limitless proliferation abilities which are capable of driving tumor growth [7] . The more 'differentiated' descendants, which account for the majority or bulk of the tumor population, may also be able to proliferate, but regenerative ability is limited [7] . Cancer stem cells were first described in patients with acute leukemia and subsequently in a variety of solid tumors [8, 9] . In breast cancer, CSC were first reported in 2003 by Muhammad Al-Hajj using CD44
? and CD24 -surface expression [10] . Since then BrCSC have been characterized based on other cell surface antigens (EpCAM ? , CD133 ? , CD90
? ) and by functional activities including enhanced efflux pumping of a Hoechst dye (side population), overexpression of aldehyde dehydrogenase (ALDH, ALDE-FLUOR assay), retention of the lipophilic dye PKH26, and tumorsphere-forming ability [11] [12] [13] [14] . BrCSC are also called tumor initiating cells that are described as having the ability to self-renew, induce tumors at low cell numbers, have low rates of cell division, exhibit chemotherapy and radiation resistance, and have gene expression profiles which differ from the more differentiated cancer cell counterparts [15] . The concept of solid tumor and particularly BrCSC is controversial with several alternative explanations for stem-like cell behaviors [11, 16] .
CSC are generally reported to be resistant to chemotherapy and radiation and BrCSC commonly lack ''targetable'' receptors like ER or HER2 [17] [18] [19] . Thus, there is considerable interest in finding therapeutic agents targeted to BrCSC. The presence of substantial numbers of BrCSC in basal-like breast cancer cell lines [10] provided the opportunity to examine the effects of TRA-8 (anti-DR5) on BrCSC enriched populations in terms of anti-DR5 mediated cytotoxicity, inhibition of tumorsphere formation in vitro, and tumorigenicity in vivo. TRA-8 is an agonistic monoclonal anti-DR5 antibody with cytotoxicity and antitumor activity in a variety of human tumor cell lines and murine tumor xenografts [20] [21] [22] [23] including basal-like breast cancer cell lines [24] .
Materials and methods

Drugs and antibodies
Adriamycin and taxol were purchased from Sigma Aldrich Chemical Co. (St. Louis, MO) and prepared as 10 mM stock solutions in distilled H 2 O or DMSO, respectively. Purified TRA-8 (IgG1) mAb was provided by Tong Zhou at the University of Alabama at Birmingham (UAB) as described previously [25] . Isotype-specific IgG1 control antibody was obtained from Southern Biotechnology Associates (Birmingham, AL). Anti-DR4 mAb 2E12 (IgG1, k) was provided by Tong Zhou (UAB). Super Killer TRAIL TM was purchased from Enzo Life Sciences International, Inc. (Plymouth Meeting, PA). Conjugated antibodies APC mouse anti-human CD44, PE-Cy7 rat antimouse CD44, and corresponding isotype control antibodies were purchased from BD Pharmingen (San Jose, CA). ALDEFLUOR kit including diethylaminobenzaldehyde (DEAB) negative control was obtained from StemCell Technologies (Durham, NC). Cleaved caspase 8 rabbit mAb and cleaved caspase 3 rabbit mAb were purchased from Cell Signaling (Billerica, MA). Secondary antibodies, Alexa fluor 405 goat anti-rabbit IgG, and Alexa fluor 647 goat anti-mouse IgG1 were purchased from Invitrogen (Carlsbad, CA).
Cells and cell culture
The 2LMP subclone of the human breast cancer cell line MDA-MB-231 was obtained from Dr. Marc Lippman (University of Miami, Coral Gables, FL) and maintained in improved MEM supplemented with 10% FBS (Hyclone, Logan, UT). Basal-like cell lines HCC38, HCC1187, HCC1143, MDA-MB-436, BT-20, and BT-549 were obtained from American Type Culture Collection (Manassas, VA) and cultured according to supplier's directions with the exception of MDA-MB-436, which was grown in DMEM supplemented with 10 lg/ml insulin, glutathione, and 10% FBS. SUM159 was obtained from Asterand (Detroit, MI) and grown according to supplier's recommendation. All cell lines were maintained in antibiotic-free medium at 37°C in a 5% CO 2 atmosphere and routinely screened for Mycoplasma contamination. Sorted cells and tumorspheres were maintained in MEGM medium (Lonza, Walkersville, MD).
Doubly enriched BrCSC isolation by flow cytometry
Basal-like cell lines were plated in T75 flasks (Costar, Cambridge, MA) in corresponding media and harvested at 75% confluence. Cells were harvested with trypsin and labeled with 1 ll of ALDEFLUOR reagent in 100 ll AL-DEFLUOR buffer per 5 9 10 6 cells and incubated at 37°C for 30 min. Cells were then labeled with APC-CD44 (1:25) and PE-CD24 (1:25) in 200 ll of ALDEFLUOR buffer on ice for 15 min. The ALDEFLUOR positive population was established by using 2 9 10 6 ALDEFLUOR labeled cells and 5 ll DEAB in 200 ll ALDEFLUOR buffer. The sorting gates were established using negative controls, DEAB and side scatter and forward scatter profiles were used to eliminate cell doublets [10, 11, 16] . Samples were sorted on a Becton-Dickinson-FACSAriaII TM or analyzed on Becton-Dickinson-LSRII TM flow cytometer (Chicago, IL). Data was evaluated using FlowJo software (Tree Star, Inc., Ashland, OR).
DR5 expression and functional caspase activation 2LMP, SUM159, and HCC1143 cell lines were harvested using cell stripper (Mediatech, Manassas, VA) to prevent cleavage of death receptor. Cells were incubated with ALDEFLUOR reagents for 30 min at 37°C. Cells were then labeled on ice with TRA-8 (IgG1) or IgG1 istotype control for 15 min. Cells were then incubated with CD44-PE-Cy7 (1:1,000), CD24-PE (1:100), and secondary antibody (Alexa-647) (1:100) for 15 min on ice. Samples were analyzed by flow cytometry for DR5 expression on the CD44
? /CD24 -/ALDH ? subpopulation. Analysis of caspase 8 and 3 activation of BrCSC was accomplished by harvesting cells using cell stripper and sorting for the ALDH ? population. Sorted cells were treated for 2 h with TRA-8 or IgG1 control (*1 9 10 6 cells with 1 lg/ml TRA-8 or IgG1 in MEGM medium ? 2% BSA). Cells were fixed with 1% paraformaldehyde for 5 min on ice and labeled with CD44-APC and CD24-PE (1:100) on ice for 15 min. Cells were then permeabilized using 3% BSA, 0.1% saponin in 200 ll PBS on ice for 15 min and labeled with cleaved caspase 3 or 8 (1:500) on ice for 15 min. Cells were incubated with secondary antibody Alexa-405 antirabbit (1:100) on ice for 15 min. Samples were kept in 0.1% saponin and analyzed by flow cytometry. Analysis was done on a minimum of three independent experiments.
Cell viability assays using ATPLite
Sorted CD44
? /CD24 -/ALDH ? cells were plated on ultralow attachment plates (Costar) at 2,000 cells per 50 ll of MEGM medium. Bulk unseparated cells were collected from total viable gates established by forward and side scatter parameters to control for any variables introduced by sorting the cells. Cells from the bulk unseparated populations were plated in optically clear 96-well black plates (Costar) in corresponding media. Sorted and bulk cells were treated with (0.1, 1, 10, 100, or 1,000 ng/ml) of TRA-8 immediately after plating and incubated for 24 h at 37°C. TRA-8 was diluted in culture medium immediately before use. Cell viability was determined by measurement of cellular ATP levels using the ATPLite luminescence-based assay (Packard Instruments, Meriden, CT) described elsewhere [26] . The manufacturer's recommended protocol was followed with the exception that all reaction volumes (culture medium and reagents) were reduced by one-half. All samples were assayed in quadruplicate and IC 50 values are reported as the median from a minimum of three independent experiments.
In vitro treatment of tumorspheres 2LMP and SUM159 cell lines were sorted for ALDH ? cells. Approximately *1 9 10 6 cells were allowed to form primary spheres at a density of 100,000 cells/ml for 3-4 days in MEGM medium. Tumorspheres were mechanically dissociated and plated in ultra-low attachment 96-well plates (Costar) at 2,000 cells per well. TRA-8 (anti-DR5), 2E12 (anti-DR4), TRAIL, IgG isotype control, adriamycin, or taxol were added to the wells and incubated at 37°C for 48 h in quadruplicate. Tumorspheres were visually counted using a reticle eye piece. Mean tumorsphere inhibition was calculated relative to untreated control spheres. At least three independent experiments were conducted per cell line in quadruplicate.
Effect of drug treatment of breast cancer cells on BrCSC population 2LMP and SUM159 breast cancer cells were plated in 6-well well culture plates at 80,000 cells/well (Costar 3516). Cells were treated with adriamycin (200 nM) or taxol (200 nM) for 48 h, or TRA-8 (10 ng/ml) for 24 h. Cells in suspension after treatment along with attached cells were harvested and incubated with Aldefluor reagent for 30 min at 37°C following manufacturer's protocol. Cells were analyzed using a LSRII TM flow cytometer (Becton-Dickinson). Cells were gated based on forward and side scatter properties for single viable cells. The signal from autofluorescence of drug treatment was accounted for in the final analysis of BrCSC ALDH marker expression.
Ex vivo treatment of BrCSC and tumor implantation CD44
? /CD24 -/ALDH ? 2LMP and SUM159 cells (1 9 10 6 ) were sorted and allowed to recover for 13 h in MEGM medium in ultra-low attachment plates at 37°C. Cells (2 9 10 4 ) were separated into treatment groups and drug or antibody was added (IgG, 20 nM), 2E12 (20 nM), TRA-8 (20 nM), and adriamycin (500 nM). Cells were treated for 3 h at 37°C and then aliquoted in 200 ll (1:1 Matrigel) and injected into the mammary fat pad of 4 week old NOD/ SCID mice (Harlan, Prattville, AL). Tumor size was determined by the product of two largest diameters. Two independent animal experiments were conducted for the 2LMP and SUM159 cell lines.
Statistical analysis
The IC 50 is the drug concentration producing the median effect of 50% cell killing which was estimated based on the Hill Equation with nonlinear regression model for each assay [27] . Due to small number of replicate experiments, a nonparametric statistical method with Kruskal-Wallis test was used for the comparison between two groups, e.g., IC 50 , percentage of tumorsphere number and ATP level [28] . The Generalized Linear Model (GLM) with PROC MIXED was used to compare the tumor size over time among experimental groups. Main effect and interaction between treatment groups and measurement time point were fitted in the model with appropriate variance and covariance structure selected. The statistical analysis was carried out with Statistical Analysis Software (SAS) version 9.2.
Results
Anti-DR5 (TRA-8) induced cytotoxicity to BrCSC enriched cells
Eight basal-like cell lines underwent dual BrCSC enrichment (CD44 ? /CD24 -/ALDH ? ) and these BrCSC enriched populations were compared with their unseparated parental cells in regard to sensitivity to anti-DR5 (TRA-8) mediated cytotoxicity ( Table 1) . As reported previously [24] , the basal-like cell lines were quite sensitive (IC 50 \ 100 ng/ml) to TRA-8 mediated cytotoxicity except for HCC1143 which was moderately resistant (IC 50 of 101-1,000 ng/ml). All the cell line BrCSC enriched cell preparations were very sensitive to anti-DR5 mediated cytotoxicity including cell line HCC1143. In 6/8 instances, the BrCSC enriched cells were significantly more sensitive than their parental cells.
DR5 expression of BrCSC enriched cells
The dual separated (CD44
) and unseparated cell preparations from 2LMP, SUM159, and HCC1143 underwent flow cytometry for analysis of cell membrane expression of DR5. As shown in Fig. 1 , cells from all cell lines were strongly positive and the unseparated (blue lines) and dual enriched (red lines) had comparable expression of DR5.
Apoptosis of anti-DR5 treated BrCSC enriched cell populations
To determine that anti-DR5 can mediate apoptosis of the BrCSC enriched cells, the 2LMP and SUM159 ALDH ? populations were incubated with anti-DR5 or control IgG for 2 h, and the CD44 ? CD24 -cell population were tested for cellular expression of activated caspase 8 and activated caspase 3. Figure 2 illustrates that a substantial portion of the 2LMP (Fig. 2a) and SUM159 (Fig. 2b ) BrCSC underwent caspase 8 and 3 activation (green lines) as compared with BrCSC exposed to control IgG (red line). This delineates that anti-DR5 triggers caspase activation and apoptosis of BrCSC doubly enriched cells over even short durations of 2-3 h.
Analysis of anti-DR5 effect on BrCSC tumorsphere formation
Tumorsphere formation has been reported as a measure of BrCSC presence in enriched cell populations [29] . Figure 3 provides the effects of anti-DR5 (TRA-8), anti-DR4 (2E12), TRAIL, adriamycin, taxol, control IgG, and control media on secondary tumorsphere formation of 2LMP (Fig. 3a) , and SUM159 (Fig. 3b) 
2-fold increase of ALDH
? cells, respectively (Fig. 4) . SUM159 cells treated with adriamycin or taxol had a 3.3-fold and 1.9-fold increase in the percentage The major requirement of BrCSC is the ability to generate fully constituted human breast cancer in immuno-compromised mice. BrCSC enriched cell populations were exposed to anti-DR5 (TRA-8), anti-DR4 (2E12), control IgG, or adriamycin for 3 h before injection of treated cells into the mammary fat pads of NOD/SCID mice (n = 5 for each group). Figure 5a illustrates that the control IgG, anti-DR4, and adriamycin treated cells generated 5/5 tumors. The IgG control mice were sacrificed on day 44 to comply 
Discussion
There is considerable interest in finding therapeutic agents that could be targeted to CSC to enhance the efficacy of treatment regimens and potentially reduce tumor resistance and relapse. We have previously shown the anti-tumor activity of an agonistic monoclonal anti-DR5 antibody (TRA-8) to 2LMP and other basal-like cell lines in vitro and in vivo [24] . Others have shown DR-mediated cytotoxicity to basal B but not basal A breast cancer cell lines [30] . Given that basal-like cell lines are enriched in CSC [5, 18] [31] .
A prior study had reported that TRAIL was able to mediate cytotoxicity to colon cancer CSC (dye efflux side population) and that this population was enriched for expression of DR4 [32] . We thus contrasted the effects of TRAIL, anti-DR4, and anti-DR5 on BrCSC tumorsphere formation. These studies demonstrated the superiority of TRA-8 over TRAIL and anti-DR4 in terms of inhibition of BrCSC tumorsphere formation. Similarly, TRA-8 was superior to anti-DR4 in inhibition of BrCSC tumorigenicity. This may reflect differences among CSC of different tumor types. Indeed, CSC from glioblastoma cell lines have been reported to be resistant to TRAIL mediated cytotoxicity [33] . These observations suggest that DR5 maybe a target on the surface of basal-like breast cancer cell lines and BrCSC by which an agonistic monoclonal anti-DR5 antibody could mediate anti-tumor activity/efficacy. Tigatuzumab is the CDR grafted, humanized version of TRA-8 which has entered clinical trials [34] . Because of these studies and others, the Translational Breast Cancer Research Consortium has recently opened a randomized phase II trial of abraxane ± tigatuzumab for metastatic triple negative breast cancer (ClinicalTrials.gov NCT01307891).
